NEW YORK (GenomeWeb News) – GlaxoSmithKline today said that it has reached an agreement to acquire the remaining 80 percent of proteomics firm Cellzome that it didn't already own for £61 million ($99 million).

The deal will provide GSK with state-of-the-art proteomic mass spectrometry and screening capabilities, the UK drug firm said. It will use Cellzome's technologies to assess drug interactions with target proteins and to help identify potential safety issues earlier in the drug discovery process.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.